Background: White matter is an early and important yet under-evaluated target of Alzheimer's disease (AD). Metabolic impairments due to insulin and insulin-like growth factor resistance contribute to white matter degeneration because corresponding signal transduction pathways maintain oligodendrocyte function and survival. Methods: This study utilized a model of sporadic AD in which adult Long Evans rats administered intracerebral streptozotocin (i.c. STZ) developed AD-type neurodegeneration. Temporal lobe white matter lipid ion profiles were characterized by matrix-assisted laser desorption/ionization-imaging mass spectrometry (MALDI-IMS). Results: Although the lipid ion species expressed in the i.c. STZ and control groups were virtually identical, i.c. STZ mainly altered the abundances of various lipid ions. Correspondingly, the i.c. STZ group was distinguished from control by principal component analysis and data bar plots. i.c. STZ mainly reduced expression of lipid ions with low m/z's (less than 810) as well as the upper range m/z lipids (m/z 964-986), and increased expression of lipid ions with m/z's between 888 and 937. Phospholipids were mainly included among the clusters inhibited by i.c. STZ, while both sulfatides and phospholipids were increased by i.c. STZ. However, Chi-Square analysis demonstrated significant i.c. STZ-induced trend reductions in phospholipids and increases in sulfatides (P b 0.00001). Conclusions: The i.c. STZ model of sporadic AD is associated with broad and sustained abnormalities in temporal lobe white matter lipids. The findings suggest that the i.c. STZ model could be used for pre-clinical studies to assess therapeutic measures for their ability to restore white matter integrity in AD.
Introduction
Alzheimer's disease (AD) is manifested by progressive behavioral changes, loss of recent memory, and declines in executive and cognitive functions (McKhann et al., 2011) . The characteristic neuropathological changes in AD include brain accumulations of hyper-phosphorylated tau (pTau)-containing cytoskeletal lesion, and increased amyloid-beta (Aβ42) deposits in plaques, vessels, and neurons (Kalaria and Ballard, 1999; Viola and Klein, 2015) . However, other more extensive and universal pathologies, including atrophy of white matter (WM), loss of neurons and synaptic terminals, neuro-inflammation, reactive astrocytosis, micro-vascular disease, and increased cellular stress with activation of the unfolded protein response (de la Monte, 2016; Hyman et al., 2012; Montine et al., 2012; Nelson et al., 2012) have received relatively little attention. Failure to attend to the full spectrum of disease could account for the persistent difficulties in rendering accurate diagnoses and repeated failure of clinical trials designed to treat just one aspect of AD (de la Monte, 2016) .
WM atrophy and degeneration in AD was first characterized in 1986 by Englund, 1986a, 1986b) and subsequently shown to represent an early abnormality that emerged in preclinical stages of disease (de la Monte, 1989) . Its main histopathological features include pallor of myelin staining with Luxol fast blue dye due to 42 (Roher et al., 2002) .
WM is largely composed of lipid-rich myelin sheaths that are synthesized and maintained by oligodendrocytes. The wrapping of myelin sheaths around axons provides insulation, ensuring efficient electrochemical conductivity. Impaired function or death of oligodendrocytes disrupts myelin homeostasis, leading to myelin loss and compromised neurotransmission, plasticity and cognition. Mechanistically, myelin breakdown could be mediated by increased susceptibility of oligodendrocytes to free radical and other types of metabolic injury (Bartzokis, 2004) .
Major CNS WM lipids include cholesterol, glycosphingolipids, i.e. cerebrosides (galactosylceramide, galactocerebroside), sulfatides (sulfated galactocerebroside, sulfogalactosylceramide), gangliosides, and phospholipids, consisting of glycerophospholipids (phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS) and plasmalogens) and sphingomyelin (Quarles et al., 2006) . Sphingomyelin is composed of ceramide plus a phosphocholine or phosphoethanolamine polar head group (Quarles et al., 2006) . Abnormal metabolism and expression of various lipids, including phospholipids and sulfatides occur in a broad range of CNS diseases (Takahashi and Suzuki, 2012) . In AD, WM cholesterol, fatty acids, myelin basic protein, and myelin proteolipid protein levels are reduced (Roher et al., 2002; Wang et al., 2004) and sulfatides in both gray and WM are substantially diminished (Han et al., 2002) .
Although the mechanisms and consequences of aberrant myelin lipid expression are not well understood, some effects can be predicted based on specific lipid functions. For example, the impairments in intracellular signaling associated with membrane phospholipid deficiencies correlate with their regulatory functions in lipid rafts and membrane receptors. Sulfatides, localized on the extracellular leaflet of myelin plasma membranes and synthesized through sulfonation of galactocerobroside (Vos et al., 1994) , regulate neuronal plasticity, memory, myelin maintenance, protein trafficking, adhesion, glial-axonal signaling, insulin secretion, and oligodendrocyte survival (Takahashi and Suzuki, 2012; Vos et al., 1994) . Correspondingly, reductions in membrane sulfatide disrupt myelin sheath structure and function, and compromise neuronal conductivity (Kolesnick and Kronke, 1998) . Sulfatide degradation via increased galactosylceramidase, sulfatidase or aryl sulfatase activities yields ceramides (Eckhardt, 2008; Sundaram et al., 1995; Vos et al., 1994 ) that promote neuroinflammation, reactive oxygen species formation, apoptosis, and dysregulated signaling through cell survival and metabolic pathways (Kolesnick and Kronke, 1998) .
Despite abundant information about AD's adverse effects on WM, the biochemical nature of its degeneration has not been well characterized due to the lack of suitable tools for efficiently studying pathologic alterations in lipid-rich myelin. Fortunately, over the past several years, major advances in technology and computational science have facilitated extension of Matrix Assisted Laser Desorption Ionization Imaging Mass Spectrometry (MALDI-IMS) to human research. MALDI-IMS is used for in situ imaging of lipids, proteins, and adducts for correlation with histopathology and molecular pathology (in situ hybridization and immunohistochemistry) (Caprioli et al., 1997) . Instruments equipped with an Nd:YAG Smartbeam laser enable time of flight (TOF; m/z) analysis for specific identification of molecules (Yalcin and de la Monte, 2015) .
For this research, we utilized MALDI-IMS to characterize temporal lobe WM myelin lipid profile abnormalities in an intracerebral Streptozotocin (i.c. STZ) model of neurodegeneration. Although STZ is best known for its toxic effects on beta cells in pancreatic islets and production of Type 1 diabetes mellitus, at low doses it causes Type 2 diabetes with peripheral insulin resistance (Bolzan and Bianchi, 2002; Koulmanda et al., 2003; Wang et al., 2011; Yan et al., 2008) , and when administered i.c., it causes AD-type neurodegeneration without damaging pancreatic islets or reducing pancreatic production of insulin (Blass et al., 2002; Blum-Degen et al., 1995; de la Monte et al., 2006; de la Monte et al., 2017; Gasparini et al., 2002; Lester-Coll et al., 2006) . The rationale for employing the i.c. STZ model is that substantial evidence indicates that the major early abnormalities in AD include reductions in brain glucose metabolism, insulin/IGF trophic factor levels, and insulin/IGF-1 signaling through phosphoinositol-3-kinase (PI3K)-Akt pathways that regulate cell survival, energy metabolism, neuronal plasticity and WM integrity (de la Monte and Tong, 2014; de la Monte and Wands, 2008; Rivera et al., 2005; Steen et al., 2005; Talbot et al., 2012) . Regarding WM, oligodendrocyte survival and function are regulated by insulin and insulin-like growth factor type 1 (IGF-1) signaling (Barres et al., 1993; Carson et al., 1993; Chesik et al., 2008 ) and brain diseases linked to insulin and IGF-1 trophic factor deficiencies or receptor resistances are associated with WM pathology (de la Monte, 2009 Monte, , 2012 Monte, , 2016 de la Monte et al., 2009 ). The i.c. STZ model is widely used because it produces neurobehavioral, histopathological, molecular, and biochemical abnormalities that mimic most aspects of sporadic AD, including amyloid-β deposition, pTau accumulations, cortical-limbic pathway degeneration, deficits in spatial learning and memory, neuroinflammation, increased oxidative stress and WM degeneration (Akinola et al., 2015; de la Monte and Wands, 2008; Paidi et al., 2015; Salkovic-Petrisic et al., 2013; Tong et al., 2016a; Wang et al., 2014) .
Methods

Experimental model
A sporadic AD model was generated in 4-week old male Long Evans rats (8/group) by administration of i.c. STZ under ketamine/xylazine anesthesia (de la Lester-Coll et al., 2006; Tong et al., 2016a; Tong et al., 2016b) . Control rats were given i.c. saline. The experiment was terminated on Day 28. Temporal lobes were dissected, snap frozen and stored at −80°C.
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS)
Frozen temporal lobes were equilibrated to −20°C in the cabinet of a Leica CM 3050 cryostat (Nossloch, Germany) and then mounted with optimum and consistent orientation onto cryostat chucks using a small drop of Tissue-Tek® optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA), such that none of the OCT contaminated the cut sections or slides. Cryostat sections (10 μm thick) were thaw mounted onto indium tin oxide (ITO) coated glass slides (Delta Technologies, Loveland, CO) and prepared for lipid analysis by sublimation coating with 200 ± 13 mg/cm 2 2,5-dehydroxybenzoic acid (DHB; SigmaAldrich Co, St. Louis, MO) as a thin uniform layer of matrix (Angel et al., 2012; Yalcin and de la Monte, 2015) . The tissue sections were dehydrated for 1 h in a vacuum desiccator, then washed 5 times with 50 mM, pH 6.4 ammonium formate (150 μl/slide/wash-5 s each) to remove salts and enhance sensitivity during spectra acquisition (Yalcin et al., 2015a; Yalcin et al., 2015b) . The slides were again dried in a vacuum desiccator for 30 min. Imaging experiments were performed using a reflectron geometry MALDI-time of flight (TOF)/TOF mass spectrometer (Ultraflextreme, Bruker Daltonics, Bremen, Germany). For analysis, a Smartbeam II Nd:YAG laser was focused onto~100 μM 2 areas. Imaging data were acquired with the mass range set to 60-2000 Da by summing 500 shots/ array position at a laser repetition rate of 1000 Hz and 25% power. To evaluate lipid profiles, imaged data were collected in the negative ion mode at a lateral resolution of 100 μM.
Data analysis
Standardized regions of interest in adjacent histological sections stained with Luxol fast blue-Hematoxylin and Eosin (LHE) were co-registered with the MALDI-TOF image. MALDI data were processed using FlexAnalysis v3.4 (Bruker Daltonics, Billerica, MA) and visualized with FlexImaging software v4.0 (Bruker Daltonics, Billerica, MA). Results were normalized to total ion counts to prevent ion suppression and variation across tissue sections or matrix preparations (Jackson et al., 2007; Yalcin et al., 2015a; Yalcin et al., 2015b) . Statistical analyses were performed using ClinProTools v3.0 (Bruker Daltonics, Billerica, MA). Phospholipids and sphingolipids were identified by comparing precursor and product ion m/z values with those catalogued in the LIPID MAPS database (http://www.lipidmaps.org/tools/index.html) and confirmed by tandem mass spectrometry (MS/MS) in the LIFT-TOF/TOF mode. In addition, lipid assignments were made based on published reports.
Inter-group comparisons were made using principal component analysis (PCA) and data bar plots with the goals of reducing dimensionality of the data sets while retaining the information present within the data corresponding to intensities and defined masses of expressed lipids. The PCA algorithm utilized reduced the number of dependent variables in each spectral set by replacing groups of intercorrelated variables with a single new variable (Shao et al., 2012) . Data bar plots scaled by calculating mean percentage changes in lipid ion expression (m/z's 600-1200) were generated in R Version 3.2 using the ggplot2 module. Differences in the mean lipid ion expression levels were compared using Student t-tests with a 5% false discovery correction. In addition, Chi-square, fractional chi-square, and Cochran-Armitage tests were used to assess proportional alterations in lipid subtypes associated with i.c. STZ treatment.
Results
Characteristics of the model
The characteristics of the model have already been reported (de la de la Monte et al., 2016; Tong et al., 2016a; Tong et al., 2016b) . In brief, i.c. STZ caused sustained deficits in motor function (rotarod) (Tong et al., 2016b) and performance on spatial learning and memory tasks (Morris Water Maze) (Tong et al., 2016a) . Neurodegeneration was associated with brain atrophy, neuronal loss, white matter degeneration, gliosis, neuroinflammation, and increased levels of amyloid-beta, phospho-Tau, and ubiquitin immunoreactivity in the temporal lobes (de la . In addition, the i.c. STZ treatments impaired signaling through the insulin and IGF-1 receptors, insulin receptor substrate proteins, and downstream pathways through phosphoinositol-3-kinase (PI3K)-Akt, and mTOR (de la , and substantially altered expression of both immature and mature oligodendrocyte myelin associated genes and proteins (de la Monte et al., 2016) .
Temporal lobe WM lipid ion profiles
Temporal lobe WM was subjected to MALDI-IMS in the negative ion mode. The Peak Statistic report identified 158 lipid ions with mass/ charge (m/z) ratios between 648.92 and 1046.7 in all samples, and 8 others that were detected in either control (n = 1) or i.c. STZ (n = 7) brains (Table 1) . Lipid assignments were made by comparing the precursor and product ion m/z values with those catalogued in the LIPID MAPS database and confirmed by MS/MS as previously described (Yalcin et al., 2015a; Yalcin et al., 2015b) . Alternatively, the lipid ion assignments were made based on published reports (Dreisewerd et al., 2007; Eckhardt et al., 2007; Fernandez-Lima et al., 2011; Gode and Volmer, 2013; Hsu and Turk, 2000; Shanta et al., 2011) .
Those analyses revealed that 1 PS was detected only in control brains, and 2 PS, 2 PE, 1 PI, 1 ST and 1 lipid that was not identified were differentially expressed in i.c. STZ WM (Table 1 ). All 8 lipid ions were expressed at low levels. The 158 lipid ions that were detected in both groups included 39 (24.7%) sulfatides, among which 12 (30.8%) were C13-isotopes; 3 (1.9%) ceramides, 1 (33%) of which was a C13-isotope of ceramide; 86 (54.4%) phospholipids, among which 25 (29.1%) were C-13 isotopes of phospholipid ions; and 20 (12.7%) not identified ( Table 2 ). Note that the percentages of C13 stable isotopes were similar for the main lipid classes. In addition, it is likely that ceramides were under-represented since they are optimally detected in the positive rather than negative ion mode (Berry et al., 2011; Lohmann et al., 2010) . Most of the 86 phospholipids were further characterized as PI (n = 46; 53.4%), PS (n = 26; 30.2%), PE (n = 9; 10.4%), or PG (n = 3; 3.5%); however, 2 (2.3%) phospholipids could not be further identified. Initial assessments of i.c. STZ's effect on WM lipid ion expression were made by comparing the peak intensity/area versus m/z profiles whereby higher peak intensity and area-under-curve values reflected greater abundances of specific lipids. Using this approach, the lipid ion profiles in control and i.c. STZ samples appeared quite similar, indicating that of the inter-group differences were most likely due to alterations in relative abundance rather than lipid composition (Fig. 1) .
Principal component analysis (PCA)
PCA was used to compare the groups with respect their overall patterns of lipid ion expression. The 3-D and 2-D plots demonstrated both overlapping and distinct distribution profiles for control and i.c. STZ samples (Fig. 2) . The overlapping components reflect shared expression of lipid ions, whereas the clearly separated regions depict long-term or sustained differential effects of i.c. STZ on WM lipid ions. Therefore, i.c. STZ altered expression of a subset of lipid ions.
Effects of i.c. STZ on lipid subtypes
To assess the effects of i.c. STZ on the expression levels of individual lipid ions, the mean percentage change in peak intensity (reflecting lipid ion abundance) was calculated for each of the 158 lipids detected (n = 8 samples/experimental group). Data bar plots generated with the R Ggplot2 module illustrate relative effects of i.c. STZ on temporal lobe WM lipid ions (Fig. 3) . Bars extended to the left of the median vertical axis indicate i.c. STZ-induced reductions in the expression of specific lipid ions, whereas those to the right reflect i.c. STZ associated increases in lipid ion expression. The i.c. STZ-induced mean increases in lipid ion expression ranged from 0.05 to 12.6%, and reductions ranged from 0.05 to 12.1%. Inter-group differences were assessed by t-test analysis with 5% false discovery rate.
Results sorted by ascending m/z values demonstrate that most of i.c. STZ-induced reductions in lipid ion expression affected ions with m/z's below 809 and between 964 and 986 ( Fig. 3A ; Table 3A ). In contrast, i.c. STZ-induced increases in lipid ion abundance were distributed in 4 clusters ranging from: 1) 870.9 to 895.8; 2) 900.8 to 921.9; 3) 926.8 to 938.8; and 4) 958.8 to 963.8 ( Fig. 3A ; Table 3A ). Re-sorting of the data bar plot in ascending order of percentage change in lipid abundance revealed which lipid subtypes were most differentially altered in expression by i.c. STZ ( Fig. 3B ; Table 3B ). t-Test analysis detected significant differences (P b 0.05) or statistical trends (0.10 N P N 0.50) for just 15 (9.5%) of the 158 lipid ions. All 5 of those reduced relative to control Fig. 2 . Principal component analysis (PCA) of IMS data acquired in the negative-ionization mode. ClinProTools was used for PCA of the total MS spectra generated from temporal lobe WM ROIs in each group. Based on spectral similarities and WM lipid profiles, two distinct but overlapping clusters were identified corresponding to control (red) and i.c. STZ (green) samples. The incomplete overlap reflects the differential effects of i.c. STZ on temporal lobe lipid ion expression.
were phospholipids, including PIP(38:4) and its C13 isotope, PE(38:5) and its C13 isotope, and PG(34:1). In contrast, 9 of the 10 that were increased (significant or trend-wise) were sulfatides including C13 isotopes or hydroxylated forms. In addition, a statistical trend increase in lipid abundance was observed for the C13 isotope of PI (38:1) (Fig. 3 , Tables 3A and 3B ). All significant and trend differences were N5% increases relative to control. Failure to reach a statistical trend or statistical significance despite similar degrees of increased or reduced lipid expression was mainly due to larger within-group variances rather than directional responses. However, the data bar plots in Fig. 3A and B clearly show clustered and similar patterned responses to i.c. STZ among lipid subtypes.
To determine how i.c. STZ altered the expression of different lipid ion subtypes, the proportional increases or reductions in temporal lobe WM phospholipids, sulfatides, C13-stable isotopes of sulfatides or phospholipids, and uncharacterized lipids were calculated (Table 4) . Data were binned into 5 groups corresponding to i.c. STZ-induced changes in lipid ion abundance as follows: 1) greater 5% increases; 2) between 1% and 5% increases; 3) no change, i.e. b 1% increases or decreases; 4) between 1% and 5% decreases; and 5) N5% reductions and analyzed using the Pearson's Chi-square test (2-sided) and Cochran-Armitage Trend Test. Among the 158 lipid ions detected by MALDI-IMS, i.c. STZ increased expression of 32 (20.3%) by N 5%, and 37 (23.4%) from 1% and 5%, but decreased expression of 11 (7%) by N 5%, and 40 (25.3%) from 1% to 5%. Only 38 (24.1%) ions were similarly expressed (b 1% difference) in i.c. STZ and control samples (Table 4) .
Chi-square tests demonstrated that i.c. STZ significantly altered the percentages of phospholipids, sulfatides, and unidentified lipids that were either increased or decreased in abundance relative to control (χ 2 = 19.46; P = 0.0126) (Fig. 4A) . Analysis of just the ST and phospholipid responses (omitting unidentified lipids) revealed highly significant effects of i.c. STZ (χ 2 = 20.46; P = 0.0004) with disproportionately greater inhibition of phospholipids compared with STs (P = 0.00001).
Comparison of i.c. STZ's effects on subdivided ST and phospholipid C12 and C13 isotope lipids demonstrated trend effects on C12 (χ 2 = 9.29, P = 0.054) and significant effects on C13 isotopes (χ 2 = 17.33, P = 0.0017). However, the Cochran-Armitage Test revealed a significant increasing trend for C12 phospholipids such that disproportionately higher percentages were inhibited relative to ST (P = 0.006), and conversely, disproportionately greater percentages of C13 phospholipids with increased expression compared with ST (P = 0.00003).
Fractional Chi-square tests showed that i.c. STZ disproportionately increased the percentages of STs in which expression was elevated between 1% and 5% above control (χ 2 = 11.6; P = 0.003), and percentages of phospholipids that had N5% reductions in their abundance relative to control (χ 2 = 8.36; P = 0.015) (Fig. 4C) . Further evidence that i.c. STZ disproportionately inhibited expression of phospholipids compared with ST was provided by the significantly greater percentages of phospholipids (C12 and C13 isotopes combined) with 1% to 5% (χ 2 = 8.27, P = 0.04) or N5% (χ 2 = 23.07, P b 0.0001) reductions in abundance relative to control (Table 4 ). Pearson's Chi-Square analysis of i.c. STZ's effects on overall phospholipid expression reached a statistical trend (P = 0.054). However, after removing the PG data which contributed just 3 lipids, the results were statistically significant (χ 2 = 17.43, P = 0.026) (Fig. 4B ). Fractional Chi-square tests demonstrated significant i.c. STZ's effects on the proportions of PE, PI and PS that were increased by N5% or between 1% and 5%, or decreased by N 5% relative to control (Fig.  4C ). The corresponding responses included increased expression in 36% of PI and 27% of PS versus none of the PE lipids, and N 5% reductions in 15% of PI and 22% of PE, but none of the PS lipids (Fig. 4B ).
Discussion
AD like diabetes mellitus is associated with insulin resistance, except brain rather than skeletal muscle is the principal target organ. In the brain, insulin is a key regulator of glucose utilization and signal transduction networks that mediate cell growth, plasticity, metabolism, neuronal survival, myelin maintenance and acetylcholine biosynthesis, and it inhibits oxidative stress and apoptosis (Craft, 2006 (Craft, , 2007 de la Monte, 2009 de la Monte, , 2012 Wands, 2005, 2008) . Proof of principle for this concept has been provided by experiments in which i.c. administration of STZ, a pro-diabetes toxin, was shown to impair spatial learning and memory and cause brain atrophy with histopathological, molecular, and biochemical abnormalities associated with AD neurodegeneration in humans . Similarly, with the model used for studies of temporal lobe WM lipids, deficits in spatial learning and memory, AD-type neuropathology including amyloid-beta, phosphotau, and ubiquitin accumulations in brain, and WM degeneration with impaired expression of myelin-associated genes and proteins have been reported (de la Monte et al., 2017; de la Monte et al., 2016; Tong et al., 2016a; Tong et al., 2016b) . WM degeneration, characterized by atrophy, loss of myelin and myelinated fibers, and gliosis (Brun and Englund, 1986a; de la Monte, 1989; Sjobeck and Englund, 2003; Sjobeck et al., 2005; Wang et al., 2004) , develops early in the course of AD. Loss of myelin and myelinated fibers adversely affects neuronal conductivity, plasticity, and brain function. Although the mechanisms are not well understood, WM pathology in AD could be mediated by impairments in insulin and IGF signaling since these pathways support oligodendrocyte survival and function, including myelin maintenance (Barres et al., 1993; Carson et al., 1993; Chesik et al., 2008) . Since myelin is largely composed of lipids, metabolic dysregulation or degeneration of oligodendrocytes could lead to altered WM lipid composition which could contribute to cognitive decline. The present study utilized an i.c. STZ model to interrogate the extent to which WM myelin lipid profiles were modulated by brain metabolic dysfunction linked to impairments in insulin and IGF signaling. Apart from its many parallels with human AD, the rationale for using the i.c. STZ model over the standard genetically manipulated models is that the latter are not known to produce the full spectrum of molecular (38:4) The table lists the m/z's of all lipid ions identified in both control and i.c. STZ white matter samples, the calculated mean percentage differences in lipid ion abundance between i.c. STZ and control, the assignment of each lipid, and results of repeated measures t-test analysis (with 5% false discovery correction). The data are sorted from lowest to highest m/z. These results are graphically depicted in Fig. 3A . # 0.10 N P N 0.05. ⁎ P b 0.05. and pathological abnormalities (including WM degeneration) that occur in sporadic AD, which accounts for the vast majority of cases. MALDI-IMS was used to acquire lipidomics data and examine effects of i.c. STZ on temporal lobe WM lipid profiles. One limitation of MALDI is that molecules are not separated prior to detection, making structural assignment of isobaric compounds quite challenging. On the other hand, the approach is more feasible for studying diseases since it enables mapping of biochemical with histopathological abnormalities. Moreover, since neurodegeneration is associated with oxidative injury, extraction procedures may lead to further artefactual molecular damage and generate differences that were not present in situ. For lipid identification, we performed tandem mass spectrometry (MS/MS) following IMS. The product ion spectra matched with individual lipids catalogued in LIPIDMAPS. However, due to their low abundances, MS/MS analysis of many lipids was inconclusive, leading us to make assignments based on published data in which the analyses of rodent brains were performed using higher resolution mass spectrometry, such as Fourier transform ion cyclotron resonance or tandem mass spectrometry. For the few instances in the Lipid MAPS search yielded isobaric lipid species, e.g. PC(16:0/24:1(15Z)) and PC(18:0/22:1(13Z)), instead of specifying the number of carbon atoms in each fatty acyl chain or positions of double bonds, we identified the lipid as PC(40:1).
The two main overall findings were that 8 low-abundance, predominantly phospholipid ions exhibited non-overlapping expression between the i.c. STZ and control groups, and the i.c. STZ treatments resulted in clustered (patterned) alterations in the expression levels of sulfatides and different phospholipids. Although the significance of differentially expressed lipids in relation to disease states is not yet understood, such findings highlight the potential contributions of dysregulated lipid metabolism as mediators or biomarkers of pathology. The altered patterns of lipid expression caused by i.c. STZ mainly corresponded to clustered shifts (increases or reductions) in relative abundance. Individually specific inter-group differences were detected for only 15 (9.5%) lipids. However, taken together, the findings are internally consistent in that both show i.c. STZ inhibition of mainly phospholipids and stimulation of sulfatides, including their corresponding C13 isotopes. These findings correspond with the previous findings of modest shifts in brain levels of individual phospholipids and sphingolipids in humans with AD (Chan et al., 2012) , and the considerable alterations in AD brain WM sphingolipid and phospholipid compositions (Brun and Englund, 1986a; de la Monte et al., 2012; de la Monte and Tong, 2014; Gottfries et al., 1996; Han et al., 2002; He et al., 2010; Wood, 2012) .
Membrane phospholipids are integral components of plasma membranes, regulating receptor functions and microdomains (lipid rafts). Reduced phospholipid levels have been correlated with insulin resistance states Vainio et al., 2005) . Therefore, the finding of disproportionately reduced phospholipid ion expression in WM of i.c. STZ treated rats could represent a consequence of brain insulin resistance. Furthermore, the reductions in WM phospholipids, including PI and PE, may have exacerbated disruption of downstream metabolic signaling, as occurs in AD (Craft, 2006 (Craft, , 2007 Rivera et al., 2005; Talbot et al., 2012) .
The i.c. STZ mediated increases in temporal lobe WM ST expression are of interest because they are largely discordant with the findings in human AD brains which exhibit sulfatide depletion rather than accumulation (Brun and Englund, 1986a; de la Monte et al., 2012; de la Monte and Tong, 2014; Gottfries et al., 1996; Han et al., 2002; He et al., 2010; Wood, 2012) . Sulfatides are glycosphingolipids synthesized by oligodendrocytes via sulfonation of galactocerobroside, which is generated from ceramide and galactose. Galactosylceramidase and sulfatidase can enzymatically degrade sufatides to ceramide and sulfate (Eckhardt, 2008; Vos et al., 1994) . Sulfatide expression marks oligodendrocyte function as these lipids are needed for normal protein trafficking, neuronal plasticity, memory, adhesion, myelin maintenance, glialaxonal signaling, insulin secretion, and oligodendrocyte survival (Takahashi and Suzuki, 2012) . Reductions in membrane sulfatide content can cause structural and functional disruption of myelin sheaths and impair neuronal conductivity. Increased degradation of sulfatide back to ceramide can lead to neuro-inflammation, generation of reactive oxygen species, and apoptosis (Kolesnick and Kronke, 1998) . Correspondingly, increased brain ceramide levels have been linked to cognitive impairment and neurodegeneration due to increased oxidative stress, neuro-inflammation, insulin resistance, and deficits in oligodendrocyte myelin-associated gene expression (de la Monte et al., 2010; Tong and de la Monte, 2009). These pathogenic processes have been established as features of AD (de la , and could be mediated by sulfatide deficiency (Han et al., 2002) and/or ceramide accumulation (de la . Of further note is that abnormal metabolism and expression of sulfatides occur in other disease states including Parkinson's disease, metachromatic leukodystrophy, diabetes mellitus, epilepsy, and viral infection (Takahashi and Suzuki, 2012) . Mechanistically, sulfatide depletion in AD could be due to reductions in cerebrosides, the precursors of sulfatides, rather than altered expression of enzyme or enzymatic dysfunction (Wood, 2012) . One potential explanation for the discordant overall i.c. STZ-associated increases in sulfatide vis-à-vis their broad reductions in AD is that the severity of neurodegeneration in the model was far less than observed in postmortem human brains, perhaps due to the relatively short duration of the model. If this is the case, the findings herein would argue that reductions in WM phospholipid expression precede sulfatide depletion, and that enhanced expression of sulfatides could represent an early compensatory response to brain metabolic dysfunction. In support of this concept is the finding that while several of the 39 sulfatides were modestly decreased in expression, 2 (m/z 792.84 and 806.82) were substantially down-regulated in the i.c. STZ brains. Questions regarding the time course x nature of altered WM myelin lipid expression in relation to neurodegeneration could be addressed by studying human brains with different degrees (durations) of AD and i.c. STZ-treated brains after more prolonged periods of observation.
An additional potential explanation for the discordant experimental and human data is that molecular and biochemical responses to disease states and their corresponding effects may differ among the species. For example, in other experimental models increased sulfatide accumulation was linked to progressive myelin loss and neurological deficits (Ramakrishnan et al., 2007) . In addition, elevated sulfatides in brain have been associated with increased neuro-inflammation (Jeon et al., 2008) , and neuroinflammation is a feature of both AD (Agostinho et al., 2010; Mehlhorn et al., 2000; Mrak, 2009 ) and the i.c. STZ model (de la . In essence, the i.c. STZ model is associated with substantial alterations in both phospholipids and sulfatides, and while the abnormalities overlap with those observed in AD, distinct differences exist that could be attributed to the manner of disease induction, differential species responses, or disease time course/duration effects. Fig. 4 . Summary effects of i.c. STZ on lipid ion expression. The aggregate effects i.c. STZ on the expression levels of different lipid sub-classes relative to control were evaluated. The percentages of lipid subtypes that were increased by N5%, between 1% and 5%, b 1%, or decreased between 1% and 5% or decreased N5% are depicted graphically. Inter-group comparisons were made for (A) sulfatides (ST), all phospholipids (Ph), and unknown (unidentified; Ukn) lipids, and (B) the three main subtypes of phospholipids expressed, phosphatidylethanolamines (PE), phosphatidylinositols (PI), and phosphatidylserines (PS). Chi-square test results (P-values) are shown in the panels. (C) Fractional Chi-Square tests were used to determine which effects of i.c. STZ were significant or reached a statistical trend. The corresponding P-values are tabulated for comparisons among ST, Ph and Ukn, between ST and Ph, and among the 3 dominant Ph's: PE, PI and PS.
